|In vitro (25°C)||DMSO||66 mg/mL (200.96 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||2 mg/mL (6.08 mM)|
|In vivo||1% DMSO/30% polyethylene glycol/1% Tween 80||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||30.45 mL||152.25 mL||304.51 mL|
|0.5 mM||6.09 mL||30.45 mL||60.9 mL|
|1 mM||3.05 mL||15.23 mL||30.45 mL|
|5 mM||0.61 mL||3.05 mL||6.09 mL|
*The above data is based on the productmolecular weight 328.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Activator|
|Storage||at -20°C 3 years Powder|
PhiKan 083, p53 stabilizing agent; preferentially binds mutated (Y220C) p53 over wild-type p53 at a site distinct from functional DNA/protei…
inhibits p53 binding to mitochondria by reducing its affinity for antiapoptotic proteins Bcl-2 and Bcl-XL.
MIRA-1 restores wild-type conformation, function and DNA binding activity to mutant p53. Induces p53 transcriptional transactivation of p21,…
Pifithrin-a is a reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription such as cyclin G, p21/waf1, and mdm2 ex…
RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2.
p53 and MDM2 proteins-interaction-inhibitor chiral is an inhibitor of the interaction between p53 and MDM2 proteins.